sulfasalazine has been researched along with Cirrhosis, Liver in 5 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resolution of liver fibrosis is associated with clearance of hepatic myofibroblasts by apoptosis; development of strategies that promote this process in a selective way is therefore important." | 1.33 | Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. ( Green, K; Iredale, JP; Mann, DA; Marek, CJ; May, MJ; Meso, M; Millward-Sadler, H; Oakley, F; Wright, MC; Zhou, X, 2005) |
| "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults." | 1.27 | Desquamative interstitial pneumonitis complicating inflammatory bowel disease of childhood. ( Fechner, RE; Sutphen, JL; Teague, WG, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadi, A | 1 |
| Niknahad, H | 1 |
| Li, H | 1 |
| Mobasheri, A | 1 |
| Manthari, RK | 1 |
| Azarpira, N | 1 |
| Mousavi, K | 1 |
| Khalvati, B | 1 |
| Zhao, Y | 1 |
| Sun, J | 1 |
| Zong, Y | 1 |
| Ommati, MM | 1 |
| Heidari, R | 1 |
| Chávez, E | 1 |
| Castro-Sánchez, L | 1 |
| Shibayama, M | 1 |
| Tsutsumi, V | 1 |
| Moreno, MG | 1 |
| Muriel, P | 1 |
| Sekine, A | 1 |
| Saito, T | 1 |
| Ito, S | 1 |
| Tsunoda, Y | 1 |
| Sumazaki, Y | 1 |
| Tanaka, T | 1 |
| Takoi, H | 1 |
| Lin, SY | 1 |
| Yatagai, Y | 1 |
| Hayasihara, K | 1 |
| Oakley, F | 1 |
| Meso, M | 1 |
| Iredale, JP | 1 |
| Green, K | 1 |
| Marek, CJ | 1 |
| Zhou, X | 1 |
| May, MJ | 1 |
| Millward-Sadler, H | 1 |
| Wright, MC | 1 |
| Mann, DA | 1 |
| Teague, WG | 1 |
| Sutphen, JL | 1 |
| Fechner, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis[NCT01051219] | Phase 3 | 45 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for sulfasalazine and Cirrhosis, Liver
| Article | Year |
|---|---|
The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicity.
Topics: Animals; Anti-Inflammatory Agents; Cholestasis; Common Bile Duct; Cytokines; Disease Models, Animal; | 2021 |
Sulfasalazine prevents the increase in TGF-β, COX-2, nuclear NFκB translocation and fibrosis in CCl4-induced liver cirrhosis in the rat.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbon Tetrach | 2012 |
Two cases of tuberculosis with multiple drug hypersensitivity after drug-induced hypersensitivity syndrome.
Topics: Aged; Allopurinol; Antitubercular Agents; Drug Hypersensitivity Syndrome; Female; Humans; Liver Cirr | 2012 |
Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis.
Topics: Animals; Anthracenes; Apoptosis; Cell Culture Techniques; Disease Models, Animal; Enzyme Inhibitors; | 2005 |
Desquamative interstitial pneumonitis complicating inflammatory bowel disease of childhood.
Topics: Adolescent; Biopsy; Colitis, Ulcerative; Humans; Liver; Liver Cirrhosis; Lung; Male; Pulmonary Fibro | 1985 |